# A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

> **NCT05481411** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 25 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Olpasiran

## Key facts

- **NCT ID:** NCT05481411
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-13
- **Primary completion:** 2023-04-05
- **Final completion:** 2023-05-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481411, "A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05481411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*